Synthesis of 4-Thiazolidinone Small Molecules as Potential Inhibitors
of the Arp2/3 Complex
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1. Introduction and Motivation

3. Synthesis Route and Mechanism

Actin is a protein found in the cytoskeleton that aids in movement and building in cells
(Figure 1). Actin related protein 2/3 (Arp2/3) complex is a structural protein that is
involved in the branching of actin (Figure 2).1 It has been found that Arp2/3 complex is
involved in instances of cancer metastasis. Tumor cells utilize the function of Arp 2/3
complex to move and proliferate.2 Small molecules are being looked at as inhibitors
for Arp2/3 complex. One breakthrough study identified two structural classes of
inhibitors via high-throughput screening.3

In general, to synthesize the molecules a mixture of aldehyde (1.0 equiv.) and amine
(2.0 equiv.) were combined with tetrahydrofuran (THF) for fifteen minutes in ice cold
conditions. Mercapto acetic acid (3.0 equiv.) was added and allowed to mix for five
minutes. DCC (1.2 equiv.) was mixed at room temperature for fifty minutes.4
Compounds were purified by column chromatography.

Figure 1:
Branching actin
filaments in the
cytoskeleton of
a cell

Figure 6: A general
synthesis outline for
the CK-869 Scaffold

5. Future Synthesis Directions
Synthesis methods that use different peptide coupling agents other than DCC
have been found to show promise of better results.5 Peptide coupling reagents
such as HBTU, PyBOP, and others could be utilized to see how the results
compare to DCC.
Only one enantiomer of CK-869 is thought to be an active inhibitor.6 In order to
separate the R and S enantiomers, chiral HPLC could be utilized (Figure 9).
Addition of a thiol at the R1 position could result in the creation of a sulfur-sulfur
bridge between the R1 position and cysteine 12. Also, alkyl groups added to the
R1 substituent, and a larger range of substituents including longer chains on the
R2 substituent are of interest (Figure 10).

Figure 2: Method of Arp2/3 complex function

4-thiazolidinones are being researched in order to increase
inhibition. For this class of molecules, insight on optimal
conditions for synthesis is being researched to increase yield
and purity of the small molecules. This is important knowledge
to gain as the potential applications are impactful. High
potency is desirable so the molecules would be useful as
research tools in the basic science of actin dynamics and
potentially useful to interfere with cancer cell metastasis.
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2. A Closer Look at CK-869

Figure 9: Separation of R and S enantiomers by using
chiral HPLC
Figure 7: Mechanism
for 4-thiazolidinones
from peptide
coupling. R1 and R2
are substituents we
are interested in
changing
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4. Specific Compounds Synthesized (Results)
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6. Further Directions
The next immediate step for this scaffold of 4thazolidinones is to conduct biochemical
assays that give results on inhibitor strength,
IC50 values.7 The goal is to increase potency by
two to three orders of magnitude. An increase
of potency would create a molecule of high
interest for basic actin research and potential
clinical anticancer applications.
The more molecules that get results, positive or
negative, in the assays allow for more insight
into what new molecules that should be
synthesized. Dr. Zoe Cournia will perform
computational docking to help us gain an idea
of possible molecules to test based off of earlier
results. Use of this iterative process is well
established in the pharmaceutical industry in
the development of first-in-class drugs.

Figure 4: CK-869 (yellow oval) disturbing the sensor
loop of Arp3, thus destabilizing the active conformation

Figure 10: Substituents of interest to change

Figure 11: Gemini XPS microplate reader
used for biochemical assays and outline of
assay components
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Figure 3: The binding site of CK-869
in Arp2/3 complex

Key Project Goals:
• Explore more structural
modifications to CK-869 to
increase potency
• Explore the mechanism
connecting CK-869 and cancer
metastasis (role of Arp2/3)
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Figure 5: Derivatives of CK-869 shown to have
anticancer activity. Potency against A549 human lung
cancer cell line, from substituent alterations in CK-869

Section 2 References: Figure 3 and 4: Hetrick, B.; Han, M. S.; Helgeson, L. A.; Nolen, B. J. Chem. Biol. 2013, 20, 701.
Figure 5: Wu, J.; Chen, Y. et al. Euro. J. Med. Chem. 2014, 80, 340-351.

Figure 8: The structures of the five molecules synthesized along with the reported yields

